Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Next Previous
Trial Profile

A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Iron overload
  • Focus Adverse reactions
  • Acronyms E.C.L.I.P.S.E.; ECLIPSE
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 26 Aug 2018 Results of a post-hoc analysis presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
  • 12 Dec 2017 Outcomes of a model developed using 12-month data from the controlled registration study (ICL670A108) and applied to both deferasirox film-coated tablet (FCT) and dispersible tablet (DT) arms of ECLIPSE trial for predicting serum ferritin levels in these patients if they continued both arms for 6-12 months, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
  • 25 Jun 2017 Results of post hoc analysis of Eclipse trial presented at the 22nd Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top